# GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

> **NCT00110721** · PHASE2 · TERMINATED · sponsor: **Galectin Therapeutics Inc.** · enrollment: 20 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** GM-CT-01 plus 5-Fluorouracil

## Key facts

- **NCT ID:** NCT00110721
- **Lead sponsor:** Galectin Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2007-06
- **Final completion:** 2008-02
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study protocol amended to a new treatment regimen: study DAVFU-006.
- **Last updated:** 2012-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110721, "GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00110721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*